| 应用 |
A highly specific non-competitive inhibitor of NAMPT |
| 产品介绍 |
FK866 (APO866, Daporinad)有效抑制烟酰胺磷酸核糖转移酶(NMPRTase)，无细胞试验中IC50为0.09 nM。Phase 1/2。 |
| 备注 |
APO866 effectively inhibits nicotinamide phosphoribosyltransferase (NMPRTase) with IC50 of 0.09 nM. Phase 1/2. |
| 生化机理 |
FK-866 has been shown to induce apoptosis by non-competitive, and specific inhibition of nicotamide phosphoribosyltransferase (NAMPT). NAMPT is a key regulatory enzyme that mediates NAD+ biosynthesis within cells. Mechanistic studies show that this compound contains an enzymatic active site of visfatin which is optimized for nicotinamide binding and inhibition. Visfatin also contains a similar structure to insulin and mimics its actions by binding to the insulin receptors. |
| 别名 |
(2E)-N-[4-(1-苯甲酰基-4-哌啶基)丁基]-3-(3-吡啶基)-2-丙烯酰胺;Daporinad; APO866; FK-866; FK 866; APO 866; APO-866;(E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)acrylamide |
